{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:47:12Z","timestamp":1782276432799,"version":"3.54.5"},"reference-count":43,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Interreg Deutschland-Danmark","award":["01-1-23 2"],"award-info":[{"award-number":["01-1-23 2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Patients with breast cancer undergoing chemotherapy with taxanes or platin derivates often develop peripheral neuropathy (CIPN). Higher-grade CIPN generally affects the patient\u2019s quality of life. Because the treatment options for CIPN are limited, early diagnosis is desirable to allow for timely modifications of the treatment. This may be facilitated with scoring tools that are ideally usable by the patients. A prospective study suggested that a recently developed self-assessment tool might be able to reveal the difference between the absence of CIPN and higher-grade CIPN. When CIPN has reached an advanced grade, alteration of the chemotherapy regimen may have only a limited effect. Therefore, it is important to know whether the new scoring tool can identify CIPN even when it is still mild. The current trial (NCT07604441) aims to identify the optimal cutoff point value for detecting mild CIPN. Given the limited sample size, the derived cutoff will be considered preliminary and will require validation in a larger independent cohort. Methods: The NEURO-BREAC-02 trial aims to identify the optimal cutoff point value of the new tool to distinguish between absent and mild CIPN after treatment with taxanes for breast cancer. Scores ranging between 0 and 44 points are reported via self-assessment supported by a neuropathy tracker. Secondly, the satisfaction of participants with the self-assessment tool is evaluated. Twenty-six participants (19 with mild CIPN and 7 without CIPN) are required, and 28 must be enrolled. Conclusions: The outcomes of the NEURO-BREAC-02 trial are considered crucial for the creation of a self-assessment tool to identify mild CIPN in patients with breast cancer and are a necessary addition to the preceding NEURO-BREAC study.<\/jats:p>","DOI":"10.3390\/jcm15134881","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:09:17Z","timestamp":1782270557000},"page":"4881","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protocol for the NEURO-BREAC-02 Trial: Evaluation of a Self-Assessment Tool for Mild Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2046-4968","authenticated-orcid":false,"given":"Dirk","family":"Rades","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Luebeck, 23562 Luebeck, Germany"},{"name":"Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Luebeck Campus, 23538 Luebeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Karolin","family":"Streubel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Luebeck Campus, 23538 Luebeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Staackmann","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Luebeck Campus, 23538 Luebeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Doehring","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Luebeck Campus, 23538 Luebeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Rody","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Luebeck, 23562 Luebeck, Germany"},{"name":"Department of Obstetrics and Gynecology, University Medical Center Schleswig-Holstein, L\u00fcbeck Campus, 23538 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0096-3547","authenticated-orcid":false,"given":"Maria Joy Normann","family":"Haverberg","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zealand University Hospital, 4000 Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-1997","authenticated-orcid":false,"given":"Martin","family":"Ballegaard","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zealand University Hospital, 4000 Roskilde, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lai, J.I., Chao, T.C., Liu, C.Y., Huang, C.C., and Tseng, L.M. (2022). A systemic review of taxanes and their side effects in metastatic breast cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.940239"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.critrevonc.2005.04.003","article-title":"Taxanes in adjuvant breast cancer setting: Which standard in Europe?","volume":"55","author":"Campone","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/tbcr-25-41","article-title":"Chemotherapy-induced peripheral neuropathy in breast cancer: A narrative review","volume":"7","author":"Brodsky","year":"2026","journal-title":"Transl. Breast Cancer Res."},{"key":"ref_5","unstructured":"(2026, May 20). Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Fr\u00fcherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Langversion 5.0, 2025, AWMF-Registernummer: 032-045OL. Available online: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/mammakarzinom\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Darby","year":"2011","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials","volume":"383","author":"McGale","year":"2014","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: A current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4149\/neo_2022_221007N992","article-title":"Prevention and therapy of chemotherapy-induced peripheral neuropathy: A review of recent findings","volume":"70","year":"2023","journal-title":"Neoplasma"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Han, Y., and Smith, M.T. (2013). Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front. Pharmacol., 4.","DOI":"10.3389\/fphar.2013.00156"},{"key":"ref_11","first-page":"2003","article-title":"Oxidative stress, mitochondrial damage and neurodegenerative diseases","volume":"8","author":"Guo","year":"2013","journal-title":"Neural. Regen. Res."},{"key":"ref_12","unstructured":"(2026, May 20). National Institutes of Health\/National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Institutes of Health\/National Cancer Institute, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): Where are we now?","volume":"160","author":"Colvin","year":"2019","journal-title":"Pain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Alliance for Clinical Trials in Oncology: Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112671","DOI":"10.1016\/j.biopha.2022.112671","article-title":"Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update","volume":"147","author":"Desforges","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","article-title":"Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors","volume":"51","author":"Eckhoff","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10549-017-4437-8","article-title":"Long-term peripheral neuropathy symptoms in breast cancer survivors","volume":"166","author":"Moeller","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2340\/1651-226X.2025.42935","article-title":"Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuropathy: A cross-sectional cohort study","volume":"64","author":"Trinh","year":"2025","journal-title":"Acta Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1529-8027.2008.00180.x","article-title":"The Utah Early Neuropathy Scale: A sensitive clinical scale for early sensory predominant neuropathy","volume":"13","author":"Singleton","year":"2008","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/jns.12595","article-title":"Corneal confocal microscopy in small and mixed fiber neuropathy-Comparison with skin biopsy and cold detection in a large prospective cohort","volume":"28","author":"Gaist","year":"2023","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Moraitis, A.M., Rose, N.B., Johnson, A.F., Dunston, E.R., Garrido-Laguna, I., Hobson, P., Barber, K., Basen-Engquist, K., and Coletta, A.M. (2023). Feasibility and acceptability of an mHealth, home-based exercise intervention in colorectal cancer survivors: A pilot randomized controlled trial. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0287152"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e3423","DOI":"10.1002\/brb3.3423","article-title":"Values and diagnostic accuracy of sensory nerve action potentials in control participants and participants with diabetes with and without clinical diabetic neuropathy, based on neuropathy scale measurements","volume":"14","author":"Abuzinadah","year":"2024","journal-title":"Brain Behav."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000535620","article-title":"Epidemiology and functional impact of early peripheral neuropathy signs in older adults from a general population","volume":"70","author":"Bronge","year":"2024","journal-title":"Gerontology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","article-title":"Total neuropathy score: Validation and reliability study","volume":"53","author":"Cornblath","year":"1999","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","article-title":"Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity","volume":"11","author":"Cavaletti","year":"2006","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e16457","DOI":"10.1111\/ene.16457","article-title":"Repurposing chemotherapy-induced peripheral neuropathy grading","volume":"31","author":"Velasco","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bardram, J.E., Westermann, M., Makulec, J.G., and Ballegaard, M. (2025). The Neuropathy Tracker-A mobile health application for ambulatory and self-administred assessment of neuropathy. PLoS Digit. Health, 4.","DOI":"10.1371\/journal.pdig.0000725"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e001350","DOI":"10.1136\/bmjno-2025-001350","article-title":"Smartphone-based patient self-assessment of neuropathy grade: A validation study of the neuropathy tracker alignment with clinical tests","volume":"7","author":"Madsen","year":"2025","journal-title":"BMJ Neurol. Open."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/jpm15110554","article-title":"Identification of chemotherapy-induced peripheral neuropathy-a self-administered scoring system tested in breast cancer survivors: Protocol of the NEURO-BREAC trial","volume":"15","author":"Rades","year":"2025","journal-title":"J. Pers. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rades, D., Streubel, M.K., Staackmann, C., Doehring, L., Rody, A., Normann Haverberg, M.J., and Ballegaard, M. (2026). A new scoring system administered by patients to identify moderate-to-severe chemotherapy-induced peripheral neuropathy: Final results of the NEURO-BREAC trial. Cancers, 18.","DOI":"10.3390\/cancers18050835"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.21873\/anticanres.17587","article-title":"Chemotherapy-induced moderate to severe peripheral neuropathy in patients receiving adjuvant radiotherapy for breast cancer","volume":"45","author":"Rades","year":"2025","journal-title":"Anticancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/978-3-319-07668-3_37","article-title":"Applying the user experience questionnaire (UEQ) in different evaluation scenarios","volume":"8517","author":"Marcus","year":"2014","journal-title":"Design, User Experience, and Usability. Theories, Methods, and Tools for Designing the User Experience"},{"key":"ref_35","unstructured":"UEQ (2026, May 20). User Experience Questionnaire. Available online: https:\/\/www.ueq-online.org."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Rades, D., Werner, E.M., Glatzel, E., Bohnet, S., Schild, S.E., Tvilsted, S.S., and Janssen, S. (2023). Early identification of pneumonitis in patients irradiated for lung cancer-final results of the PARALUC trial. Cancers, 15.","DOI":"10.3390\/cancers15020326"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/09622802231151210","article-title":"Revisiting sample size planning for receiver operating characteristic studies: A confidence interval approach with precision and assurance","volume":"32","author":"Shu","year":"2023","journal-title":"Stat. Methods Med. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/14656566.2025.2455445","article-title":"One-year incidence of chemotherapy-induced peripheral neuropathy in oxaliplatin- or taxane-based chemotherapy: A multicenter, prospective registry study (MiroCIP study)","volume":"26","author":"Misawa","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.21037\/apm-24-154","article-title":"Chronic chemotherapy-induced peripheral neuropathy: Living with neuropathy during and after cancer treatments","volume":"14","author":"Rahman","year":"2025","journal-title":"Ann. Palliat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2016.0383","article-title":"The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling","volume":"73","author":"Kolb","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"151687","DOI":"10.1016\/j.soncn.2024.151687","article-title":"Fall risk associated with taxanes: Focus on chemotherapy-induced peripheral neuropathy","volume":"40","author":"Visovsky","year":"2024","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104424","DOI":"10.1016\/j.breast.2025.104424","article-title":"Chronic chemotherapy-induced peripheral neuropathy and pain following paclitaxel versus docetaxel in breast cancer survivors: A cross-sectional study","volume":"80","author":"Gehr","year":"2025","journal-title":"Breast"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lee, K.T., Bulls, H.W., Hoogland, A.I., James, B.W., Colon-Echevarria, C.B., and Jim, H.S.L. (2024). Chemotherapy-induced peripheral neuropathy (CIPN): A narrative review and proposed theoretical model. Cancers, 16.","DOI":"10.3390\/cancers16142571"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4881\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:03:50Z","timestamp":1782273830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":43,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15134881"],"URL":"https:\/\/doi.org\/10.3390\/jcm15134881","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}